TP53, STK11, KEAP/NFE2L2 gene mutations have been shown to be associated with KRAS-mutant lung cancers, and controversial prognostic values of the co-mutations have been declared along with different therapeutic outcomes in multiple clinical trials [8,9,10]. This evidence concerns the gene KRAS and lung carcinoma.